CYP19A1 and cancer: Another trial using the aromatase inhibitor exemestane also showed a strong reduction of 53% for all cancers and a 65% reduction for invasive cancers compared with placebo.22 Overall, the aromatase inhibitors are more active than tamoxifen, both for preventing disease recurrence and reducing the development of new cancers.